Pyruvate oxidation in Charcot-Marie-Tooth disease.
Significant differences were found in pyruvate oxidation of disrupted skin fibroblasts from patients with Charcot-Marie-Tooth disease (CMT) or neuromuscular disease controls and normal controls, but there was a similar oxidative defect in both disease groups. "Heritable heterogeneity in situ" and additional enzyme faults may explain the normal activity of pyruvate dehydrogenase in some explants, and the lack of correlation between enzyme activity and CMT symptoms. Since experimental, histochemical, and microscopic studies support the concept of localized hypoxia in perineural or neural cells in CMT, the peripheral location of the defect suggests an inherited susceptibility to environmental influences in these cells.
D000328:Adult; D002607:Charcot-Marie-Tooth Disease / Q000378:metabolism*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D005621:Friedreich Ataxia / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009133:Muscular Atrophy / Q000378:metabolism*; D009468:Neuromuscular Diseases / Q000378:metabolism*; D010084:Oxidation-Reduction; D011768:Pyruvate Dehydrogenase Complex / Q000378:metabolism; D011773:Pyruvates / Q000378:metabolism*; D012583:Schwann Cells / Q000378:metabolism
D011768:Pyruvate Dehydrogenase Complex; D011773:Pyruvates